Clinical Trials

Beaumont Health System, with three hospitals in the northern Detroit suburbs serving southern Michigan and beyond, is a highly productive contributor to clinical trials across the nation. The Beaumont Research Institute, established by the hospital’s Board of Trustees in 1966, strengthens Beaumont's ability to conduct medical research and to provide a research training experience for the medical staff and participants in graduate medical education programs.

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI, FORMERLY CAZ104) VERSUS DORIPENEM FOLLOWED BY APPROPRIATE ORAL THERA

RECAPTURE I Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Status: open and enrolling

Approval Date: 7/18/2012

The purpose of this study is to compare the effects of two drugs (Ceftazidime Avibactam compared to Doripenem) for treating hospitalized patients with complicated urinary tract infections.


A RANDOMIZED, DOUBLE-BLINDED, ACTIVE-CONTROLLED STUDY OF CB-183,315 IN PATIENTS WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA (PROTOCOL NUMBER: LCD-CDAD-11-06)

A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Status: open and enrolling

Approval Date: 6/8/2012

The purpose of this study is to evaluate how well CB-183,315 treats Clostridium Difficile Associated Diarrhea as compared to vancomycin.


SWOG S1008 (CURVES): FEASIBILITY STUDY OF PHYSICAL ACTIVITY AND DIETARY CHANGE WEIGHT LOSS INTERVENTION IN BREAST AND COLORECTAL CANCER SURVIVORS, PHASE II

SWOG S1008 (CURVES): This phase II trial studies how well exercise, diet, and counseling work in improving physical activity and weight loss in overweight women who are breast and colorectal cancer survivors.

Status: open and enrolling

Approval Date: 5/3/2012

Physical activity, diet, and counseling may help breast and colorectal cancer survivors to lose weight and improve their quality of life.  This phase II trial studies how well exercise, diet, and counseling work in improving physical activity and weight loss in overweight women who are breast and colorectal cancer survivors.

 


SWOG S1008: FEASIBILITY STUDY OF A PHYSICAL ACTIVITY AND DIETARY CHANGE WEIGHT LOSS INTERVENTION IN BREAST AND COLORECTAL CANCER SURVIVORS, PHASE II

SWOG S1008: FEASIBILITY STUDY OF A PHYSICAL ACTIVITY AND DIETARY CHANGE WEIGHT LOSS INTERVENTION IN BREAST AND COLORECTAL CANCER SURVIVORS, PHASE II

Status: open and enrolling

Approval Date: 5/3/2012

RATIONALE: Physical activity, diet, and counseling may help breast and colorectal cancer survivors to lose weight and improve their quality of life.  PURPOSE: This phase II trial studies how well exercise, diet, and counseling work in improving physical activity and weight loss in overweight women who are breast and colorectal cancer survivors.


A MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP TRIAL TO COMPARE THE EFFICACY AND SAFETY OF THE SUFENTANIL NANOTAB® PCA SYSTEM/15 MCG TO INTRAVENOUS PATIENT-CONTROLLED ANALGESIA WITH MORPHINE FOR THE TREATMENT OF ACUTE POST-OPERATIVE PAIN

Status: open and enrolling

Approval Date: 4/30/2012

The study is intended to show that the Sufentanil NanoTab PCA System is as effective as morphine intravenous patient-controlled analgesia (IV PCA) for treating pain after surgery. Each patient will use either the Sufentanil NanoTab PCA System or morphine IV PCA to treat their pain for at least 48 hours and up to 72 hours after surgery while in the hospital.